Journal article icon

Journal article

Bevacizumab--current status and future directions.

Abstract:

Angiogenesis is crucial to tumour initiation, survival and metastasis. Vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors in cancer development. Bevacizumab (a humanised monoclonal antibody against VEGF) has a reasonable safety profile and proven efficacy in a phase III trial in advanced colorectal cancer. Efficacy of Bevacizumab also looks promising in non small cell lung cancer, renal cancer and a variety of other solid tumours. Questions still sur...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1093/annonc/mdi208

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, Clinical Lab Sciences, Biomedical Research Centre
Role:
Author
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume:
16
Issue:
7
Pages:
999-1004
Publication date:
2005-07-05
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
URN:
uuid:8cd17d94-c444-48de-aeb4-ae314729f4f5
Source identifiers:
175120
Local pid:
pubs:175120

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP